Pharmacogenomic Testing for Antipsychotic and Antineurological medications is a gene detection product based on the sequencer independently developed by CYGNUS. It analyzes 55 genes associated with 80 common drugs used to treat mental and neurological diseases. Based on the genetic test results, doctors can predict the drug efficacy and potential adverse reactions, enabling them to develop individualized and precise medication plans for each patient.
High efficiency and accuracy
Authoritative guidance
Convenient operation
Patients taking antipsychotic and antineurological drugs for the first time.
Patients taking multiple medications simultaneously or for an extended period.
Patients who have an unsatisfactory response to a particular drug.
Patients who have experienced adverse drug reactions themselves or among their family members.
Certain groups (those with impaired liver or kidney function, the elderly, children, etc.).
People who prioritize safe medication.
Individualized precision medicine
Provide reference for clinical rational drug use
Improve drug efficacy
Reduce adverse drug reactions
Informed consent
Sample collection
Nucleic acid extraction
Library preparation
Next generation sequencing
Data analysis
Report distribution
7 to 10 working days after receiving qualified samples.